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Abstract
Background: Barrett’s esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic
surveillance in Barrett’s esophagus has been debated because of the low incidence of esophageal adenocarcinoma in
Barrett’s esophagus. Moreover, high inter-observer and sampling-dependent variation in the histologic staging of dysplasia
make clinical risk assessment problematic. In this study, we developed a 3-tiered risk stratification strategy, based on
systematically selected epigenetic and clinical parameters, to improve Barrett’s esophagus surveillance efficiency.
Methods and Findings: We defined high-grade dysplasia as endpoint of progression, and Barrett’s esophagus progressor
patients as Barrett’s esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade
dysplasia or esophageal adenocarcinoma. We analyzed 4 epigenetic and 3 clinical parameters in 118 Barrett’s esophagus
tissues obtained from 35 progressor and 27 non-progressor Barrett’s esophagus patients from Baltimore Veterans Affairs
Maryland Health Care Systems and Mayo Clinic. Based on 2-year and 4-year prediction models using linear discriminant
analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), Barrett’s esophagus
specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. This 3-tiered stratification
method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model. Progression-free
survivals differed significantly among the 3 risk groups, with p=0.0022 (HR vs. IR) and p,0.0001 (HR or IR vs. LR).
Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction
accuracy.
Conclusions: This 3-tiered risk stratification strategy has the potential to exert a profound impact on Barrett’s esophagus
surveillance accuracy and efficiency.
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Introduction
Barrett’s esophagus (BE) is a premalignant condition in which
normal squamous epithelium is replaced by a specialized
metaplastic, small intestine-like, columnar lining [1]. BE predis-
poses patients to the future development of esophageal adenocar-
cinoma (EAC) [1,2]. The molecular mechanism of the Barrett’s
esophagus carcinogenic sequence (Barrett’s esophagus mucosa,
mild and severe dysplasia, to esophageal adenocarcinoma) has not
been fully understood. It is believed that long-term inflammation
due to gastro-esophageal reflux may cause genetic and epigenetic
alterations in Barrett’s esophagus, and that accumulation of these
genetic and epigenetic alterations would lead the acquisition of
malignant characteristics in the Barrett’s cells, such as dysregulated
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1890cell proliferation, impaired apoptosis, and angiogenesis. As genetic
alterations, loss of p16 gene expression (by deletion), the loss of p53
expression (by mutation and deletion), the increase in cyclin
expression, and the losses of Rb, APC as well as various
chromosomal loci in the Barrett’s esophagus have been reported
[3]. In addition, promoter hypermethylation of tumor suppressor
genes (p16, APC, RUNX3, HPP1, TIMP3, etc.) have been
observed in the course of Barrett’s esophageal carcinogenesis [4].
Because of this increased cancer risk, patients with BE
traditionally undergo endoscopic surveillance at regular intervals,
usually every two to three years if no additional abnormal findings
are present [1,5]. Therefore, patients often undergo as many as ten
or more surveillance endoscopies during a lifetime. In the United
States, there are approximately 86.2 million whites between the
ages of 45 and 80 years [6]. With a presumed BE prevalence rate
of 1.6% [7] for whites, approximately 1.38 million of these subjects
have BE. However, because the incidence of EAC in BE is
uncommon (approximately 1/200 patient-years), most surveillance
endoscopies in BE patients do not detect cancer. Therefore,
Barrett’s esophagus surveillance would benefit from effective
markers to stratify patients according to their level of cancer
progression risk.
The currently accepted marker for cancer risk is histologic
dysplasia, with high-grade dysplasia (HGD) being considered more
accurate than low-grade dysplasia (LGD) [8,9]. In many centers,
confirmed HGD is treated in the same manner as is early-stage
EAC, by endoscopic mucosal ablation [10,11], photodynamic
therapy [10], or surgical esophagectomy [12]. In contrast to HGD,
the predictive value of LGD for cancer risk assessment is
controversial [9,13]. Moreover, poor reproducibility (high inter-
observer variation [8,14]) in histologic assessment often makes
clinical risk assessment problematic. Thus, more accurate tissue-
based biomarkers capable of predicting the risk of progression to
HGD or EAC would be highly useful.
For the past several years, several groups have studied the role
of DNA methylation in esophageal EAC development and
progression [4]. Aberrant DNA methylation occurs early in this
process, specifically in BE, and methylation increases in frequency
in LGD and HGD, becoming most common in EAC [4,15]. We
have shown that certain tumor suppressor genes that undergo
methylation in BE can function as biomarkers, predicting whether
BE patients will or will not develop HGD or EAC [15].
In actual clinical circumstances, it is difficult to develop
prediction models exhibiting both high sensitivity and specificity.
When the cutoff point of a prediction outcome is selected to
maximize sensitivity, specificity will suffer, and false positives will
increase. Conversely, if the cutoff point of a prediction outcome is
chosen for high specificity, sensitivity will be lower. To solve this
dilemma, we propose a 3-tiered stratification approach. With this
method, patients are stratified into either high-risk (HR),
intermediate-risk (IR), or low-risk (LR) groups. In the current
manuscript, we demonstrate the prediction accuracy, statistical
significance, and potential clinical impact of this three-tiered risk
stratification system.
Materials and Methods
HGD as an outcome endpoint
HGD and EAC are not the same biological or clinical entity.
Thus, combining them into a single neoplastic progression
endpoint may appear nonstringent [15]. However, at the level of
clinical utility, a pronounced shift in management strategy (i.e.,
more intensive endoscopic surveillance and/or therapeutic
intervention) occurs when HGD is diagnosed in BE [10]. For
this reason, the progression endpoint was defined as either HGD
or EAC.
Definition of Barrett’s esophagus progressor patients and
specimens
Previously [15], we defined BE progressor patients as BE subjects
with either no dysplasia or LGD who later developed HGD or
EAC, while progressor specimens were defined as any BE tissues
obtained prior to the progression endpoint. However, in the
clinical setting, it is important to know whether or not BE will
progress prior to the next scheduled endoscopy. For this reason, in
the current study, progressor specimens (P) were divided into 3
subgroups: P(0-2), P(2-4), and P(4-), defined as BE or LGD tissues
obtained at 0–2 years, 2–4 years, or more than 4 years prior to the
progression endpoint, respectively. Similarly, non-progressor specimens
(NP) were defined as BE or LGD tissues obtained at 0–2 years
[NP(0-2)], 2–4 years [NP(2-4)], or more than 4 years [P(4-)] before
the non-progression follow-up date.
Patients and Tissues
Patients undergoing endoscopy at the University of Maryland
Medical Center, the Baltimore VA Hospital, and the Mayo Clinic
provided written informed consent under a protocol approved by
the Institutional Review Boards at each respective institution.
Biopsies were taken using a standardized protocol. At each
endoscopy, four-quadrant biopsies were obtained at 2-cm intervals
throughout the grossly apparent BE segment (or at 1-cm intervals
on follow-up after an endoscopy with LGD). Research tissues were
obtained from aliquots of grossly apparent Barrett’s epithelium.
Simultaneously obtained parallel aliquots were sent for histological
examination. Diagnoses of BE and dysplasia were made by two
experienced gastrointestinal pathologists at the two participating
institutions (T-TW and HGY).
We used an objective criteria for distinguishing LGD and HGD
that has been published previously [14] (Figure 1). A total of 118
tissue specimens derived from 62 patients with BE constituted the
subjects of this study (Table 1).
Protocols for DNA extraction, bisulfite treatment and
quantitative methylation-specific PCR (MSP)
Tissue specimens were snap-frozen immediately following
biopsy or surgical removal and stored in liquid nitrogen until
further processing. Genomic DNA from clinical specimens was
extracted using a DNeasy kit (Qiagen, Valencia, CA). DNA was
treated with bisulfite to convert unmethylated cytosines to uracils
prior to MSP, as described previously [16,17]. DNA methylation
status and levels of three genes (p16, HPP1, and RUNX3) were
determined by real-time quantitative MSP using an ABI 7700
Sequence Detection (Taqman) System, as described previously
[16,17]. Primers and probes for quantitative MSP were as
described for p16 [18], HPP1 [16], ACTB [18], and RUNX3
[15]. A normalized methylation value (NMV) reflecting the
percentage of DNA methylated for the gene of interest (GoI)
was defined as follows: NMV=1006(GoI-S/GoI-FM)/(ACTB-S/
ACTB-FM), where GoI-S and GoI-FM represent GoI methylation
levels in the specimen and fully methylated DNAs, respectively,
while ACTB-S and ACTB-FM correspond to b-actin in the
specimen and fully methylated (FM) DNAs, respectively.
Database construction
The database contained 3 clinical parameters (patient’s sex, BE
segment length (SL), and pathologic assessment: purely metaplastic
BE/BE with indefinite dysplasia vs. LGD), and 4 methylation-
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HPP1 [16], and RUNX3 [15] and methylation index (MI)).
Whether 0, 1, 2, or all 3 of these genes were methylated was scored
numerically as the methylation index (M.I.). The methylation
status of each gene in each tissue was dichotomized into negative
or positive categories, according to an optimal NMV cutoff level
determined by ROC curve analysis. Methylation status cutoff
points for the 2-year prediction model [P(0-2) vs. P(2-4), P(4-), and
NP] were 23.4%, 4.4%, and 2.2% for HPP1, p16, and RUNX3,
respectively. Methylation status cutoffs for the 4-year prediction
model [P(0-2) and P(2-4) vs. P(4-) and NP] were 16%, 1.12%, and
0.17% for HPP1, p16, and RUNX3, respectively. Cutoffs of the
NMV for the 4-year prediction model were lower than those for
the 2-year model, possibly because epigenetic alterations were less
widespread in progressor tissues at 4 years than at 2 years prior to
progression. Thus, 4 clinical features and 4 gene methylation
parameters were used to generate prediction models.
Establishment of prediction models for BE progression
To stratify patients into 3 groups, viz., high-risk (HR),
intermediate-risk (IR), or low-risk (LR), we established two
prediction models using linear discriminant analysis (LDA). To
select the HR group in the 2-year prediction model, only P(0-2)
specimens were defined as progressors for LDA, while all other
specimens were defined as nonprogressors. To obtain a prediction
value for each specimen, leave-one-out crossvalidation (LOOCV)
was performed. Prediction model accuracy was assessed by
measuring the area under the ROC curve (AUROC). These
models generated prediction output values ranging from 0 to 1,
representing highest to lowest risk, respectively. Cutoff points of
prediction model outputs defining the HR group were chosen for
90% specificity in order to minimize the number of unnecessary
endoscopies (Figure 2A). To select the LR group in the 4-year
prediction model, both P(0-2) and P(2-4) specimens were defined
as progressors for LDA, while other specimens were defined as
nonprogressors. Cutoff points of prediction model outputs defining
the LR group were chosen to achieve 90% sensitivity, in order to
minimize failure in detecting progressor patients (Figure 2B). The
IR group was defined as specimens belonging to neither the HR
nor the LR groups.
When constructing prediction models using multiple parame-
ters, it is important to choose the most optimal parameter set [19].
In the current study, the most optimal parameter set was defined
as that possessing the highest AUROC value among 127 (=2
721)
possible combinations of the 4 epigenetic and 3 clinical
parameters.
Additional statistics
Detailed methods of permutation analysis and incremental
value analysis are described in Text S1. The progression-free
survival of patients in each risk category was analyzed using the
Kaplan-Meier method and log-rank testing for statistical signifi-
cance of differences in progression-free survival. A p-value of less
than 0.05 was considered significant. All LDA, LOOCV, and
AUROC calculations were performed using Matlab, v.7.0
(Mathworks, Natick, MA). The remaining statistical calculations
were performed using STATISTICA v.6.1 (Statsoft, Tulsa, OK).
Results
Association between epigenetic parameters and BE
neoplastic progression
The NMV of HPP1, p16, and RUNX3 in each specimen is
plotted in Figures 2A, 2B, and 2C, respectively. For the 2-year
prediction model, only P(0-2) specimens were defined as positive
for progression, while others were classified as progression-
Figure 1. H&E staining of biopsy specimens from patients with Barrett’s esophagus. Objective criteria that were used to distinguish LGD
and HGD have been published previously [14].
doi:10.1371/journal.pone.0001890.g001
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genes in group P(0-2) were significantly higher than their
corresponding NMVs in groups P(2-4), P(4-), and NP
(p=0.0005, 0.0004, ,0.0001 for HPP1, p16, and RUNX3,
respectively). For the 4-year prediction model, P(0-2) and P(2-4)
specimens were both defined as positive for progression, while P(4-)
and NP specimens were classified as progression-negative for LDA.
NMVs of all 3 genes in groups P(0-2) ann P(2-4) were significantly
higher than their NMVs in groups P(4-) and NP (p=0.0006,
0.0198, and 0.0018 for HPP1, p16, and RUNX3, respectively). The
discriminant formula for 2- and 4-year prediction models are
described in Text S1.
In addition, the relationship between MI and BE progression
is displayed in Table 2. the MI of progression-positive (*) and
-negative (
1) specimens for both the 2-year and 4-year predictions
differed significantly by Chi-square testing (p,0.00001).
A combined prediction model of BE neoplastic
progression
Figure 3A demonstrates the best ROC curve for 2-year
prediction, based on the 4 parameters of SL, pathology status, p16
and MI. The AUROC, specificity, and sensitivity of this model
Figure 2. Methylation status of HPP1, p16, and RUNX3.
Normalized methylation values (NMVs) of HPP1 (1A), p16 (1B), and
RUNX3 (1C) are shown. p: p-value of t-test. NMVs of genes in
R
progression-positive cases [P(0-2) and P(0-2)+P(2-4) for the 2-year and
4-year models, respectively] were significantly higher than NMVs of
progression-negative (P(2-4)+P(4-)+NP and P(4-)+NP for the 2-year and
4-year models, respectively).
Table 1. Numbers of Tissue Samples and Patients,
Classifications, and Sources.
A) Numbers of Tissue Samples.
P(0-2) P(2-4) P(4-) NP total
Institute
MAYO 6 11 14 0 31
UMD 11 7 3 66 87
Pathology
BE 10 13 13 64 100
L G D 7 54 21 8
total 17 18 17 66 118
B) Numbers of Patients.
non-Progressor
(n=34) Progressor (n=28)
Pathology BE LGD HGD EAC Total
Institute
MAYO 0 0 12 (5)* 7 19
UMD 27 7 5 (1)* 4 43
total 27 7 17 (6)* 11 62
P(0-2), P(2-4), and P(4-): progressor samples obtained 0–2 years, 2–4 years, or
more than 4 years before the progression date, respectively; NP: non-
progressor samples; MAYO: Mayo Clinic Foundation; UMD: University of
Maryland and VA Baltimore Medical Centers; S.D.: standard deviation; BE: non-
dysplastic Barrett’s esophagus; LGD: low-grade dysplasia, HGD: high-grade
dysplasia; EAC: esophageal adenocarcinoma; Pathology: for non-progressor
patients, the most neoplastically advanced pathology; for progressor patients,
pathology at the study endpoint;
*: number of patients developing EAC
subsequent to a diagnosis of HGD.
doi:10.1371/journal.pone.0001890.t001
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90.1%, and 58.8%, respectively. Figure 3B displays the best
ROC curve for 4-year prediction using the 3 parameters of SL,
pathology, and MI. The AUROC, specificity, and sensitivity of the
4-year model were 0.7910 (95% C.I.: 0.6968–0.8853), 91.4%, and
51.8%, respectively. On ROC curves, prediction output values for
the 2-year (0.28) and 4-year (0.745) prediction models attained
90% specificity and 90% sensitivity, respectively, therefore these
output values were selected as cutoffs to define risk levels (HR or
LR; see above).
Next, to unify this algorithm, a 363 contingency table was
generated from two 262 contingency tables for the 2-year and 4-
year prediction models (Figure 4). Among 118 specimens, 20, 52,
and 46 specimens were stratified into HR, IR, and LR groups,
respectively. Theoretically, specimens could have met both the
HR (,0.28 for 2-year model) and the LR (.0.745 for 4-year
model) criteria simultaneously. However, in actuality, such an
internally contradictory specimen did not occur in the current
study. Based on the combined prediction model, this 3-tiered
stratification procedure could save more than 5300 endoscopes per
year in the United States (Figure S1). In addition, the
permutation procedure suggested that our observed results were
unlikely to have occurred by chance (Figure S2).
Progression-free survival in the three risk tiers
Three Kaplan-Meier curves showed a statistically significant
difference in progression-free survival among the three risk tiers
defined by the combined LDA model (Figure 5). The LR group
had the best progression-free survival, significantly better than
both the IR and HR groups (p,0.0001, logrank test). The HR
group had the worst progression-free survival, significantly shorter
than both the IR (p=0.0022, logrank test) and LR groups. The IR
group had a progression risk significantly different from the other
2 groups. Thus, these 3 specimen groups classified by the
combined model assigned progression risk in a meaningful
manner.
Time-course analysis of risk prediction in each patient
Criteria of a good biomarker require not only its prediction of
outcomes to be highly accurate in cross-sectional studies, but also
its changes in value to reflect clinical disease course in longitudinal
studies. Therefore, we performed a time-course analysis. In
progressor patients, progression risk should increase or be high
at least in the short time before the progression, whereas
progression risk in non-progressor cases should not increase over
time. Figure 6 demonstrates longitudinal change in risk according
to this prediction model in patients who contributed multiple tissue
specimens. In actuality, among 16 progressor patients (case #1–
16), five HR specimens from 4 patients (cases #4, 6, 11, and 12)
were reduced to IR during their follow-up BE surveillance period.
However, all 4 cases progressed to HGD at the end of their follow-
up period. This finding suggests that even if a BE patient
previously diagnosed as HR is reduced to IR at a follow-up
endoscopic biopsy, this BE patient should be followed at the HR
time interval (i.e., once yearly), rather than at the IR interval (once
every 2 years). In addition, there was not a single patient whose
risk assessment was reduced from HR to LR. In contrast, risk
assessments for all 11 non-progressor patients (cases #17–27)
stayed in LR or IR, while no non-progressor patient’s risk
assessment increased to HR.
In patients with marginal risk levels, risk assessment sometimes
fluctuated between LR and IR. Specifically, ‘‘Upgrading’’ of risk
from LR to IR occurred in 4 non-progressor patients, as well as in
2 progressor patients more than 5 years before progression.
Conversely, risk ‘‘downgrading’’ from IR to LR was observed in 3
non-progressor patients, as well as in one progressor patient (case
#15) more than 6 years prior to progression.
Incremental value analysis
In Table 3, differences between AUROCs in parameter sets
with (plus) vs. without (minus) a given parameter represent the
portion contributed to prediction accuracy of each parameter (i.e.,
its incremental value). In both the 2-year and 4-year prediction
models, methylation index (MI) exerted the greatest impact on
Figure 3. Best ROC curves of 2- and 4-year prediction models.
A: For the 2-year prediction model, the best AUROC (0.8387) was
obtained using 4 parameters: SL, pathology, p16, and methylation index
(MI). Based on this ROC curve, we chose an output value cutoff point
defining the HR group to maximize specificity (.90%, red area) rather
than sensitivity. B: For the 4-year model, the best AUROC (0.7910) was
achieved using 3 parameters: SL, pathology, and MI. Based on this ROC
curve, we selected an output value cutoff point defining the LR group
to maximize sensitivity (.90%, red area) rather than specificity.
doi:10.1371/journal.pone.0001890.g003
Table 2. Methylation Index (MI) and Barrett’s progression.
A. 2-year prediction model
MI Sample group Total
*P(0-2)
1P(2-4)
1P(4-)
1NP
0 1343 7 4 5
1 4971 8 3 8
2 22481 6
3 1 0 4231 9
Total 17 18 17 66 118
B. 4-year prediction model
MI Sample group Total
*P(0-2) *P(2-4)
1P(4-)
1NP
0 1243 4 4 1
1 3431 6 2 6
2 3571 2 2 7
3 1 0 7342 4
Total 17 18 17 66 118
Methylation index of 118 samples were shown. The dichotomization cutoff point
of NMV for each gene (methylated vs. unmethylated) was different between 2-
year and 4-year model. Therefore, the MI in some samples were different
between 2-year and 4-year model. MI of positive (
*) and negative (
1) cases were
significantly different by chi-square test (for both tables, p,0.00001).
doi:10.1371/journal.pone.0001890.t002
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prediction models, respectively), while pathology (non-dysplastic
BE vs. LGD) was the second-most influential parameter (0.0542
and 0.0462 in the 2-year and 4-year prediction models,
respectively).
Discussion
Compared to the general population, BE patients have a 30-125-
fold increased risk of developing EAC [20]. Therefore, periodic
endoscopic surveillance is generally practiced in the management of
BE patients [21]. EAC detected during BE surveillance tends to
occur at an earlier stage and have a better prognosis than EAC
found in the non-surveillance setting [22,23]. However, in terms of
cost-effectiveness, the impact of current BE surveillance recom-
mendations is controversial [24,25], because the progression rate of
BE to EAC is very low. Thus, stratification of BE patients to
improve BE surveillance efficiency would be beneficial in terms of
cost-effectiveness, as well as represent an improvement in quality of
life due to diminished anxiety and inconvenience.
Figure 4. Combining the 2-year and 4-year prediction models. A and B: 262 contingency tables for the 2-year and 4-year prediction models,
respectively. Cutoff points for the 2-year and 4-year model output values were chosen to attain 90% specificity and sensitivity, respectively, as
described above (Figure 3). C: combined 363 contingency table. Red and blue cross-lines correspond to red and blue lines in A and B. P(0-2), P(2-4),
P(4-): specimens obtained from progressor patients ,=2 years, 2–4 years, or .4 years prior to progression, respectively. NP: specimens derived from
non-progressor patients with more than a 4-year follow-up period.
doi:10.1371/journal.pone.0001890.g004
Figure 5. Progression-free survival in the 3 risk tiers. Kaplan-
Meier survival curves for each of the 3 risk tiers are shown. The 2-year
progression-free survival rates of HR, IR, and LR were 45%, 88.5%, and
97.8%, respectively. Four-year progression-free survival rates were 35%,
63.5%, and 93.5%, respectively. Differences in progression-free survival
among these 3 risk tiers were statistically significant (log-rank test).
doi:10.1371/journal.pone.0001890.g005
Figure 6. Changes in 3-risk-group prediction during follow-up.
The horizontal axis represents the time interval preceding the date of
progression or nonprogression. Among 62 patients, 27 patients
underwent biopsies at multiple timepoints before progression. Each
green bar represents the follow-up period of each patient, and each
circle shows the timing of biopsies and the risk level prediction
(designated by each circle’s color). Vertically overlapped circles with
arrows indicate multiple tissue specimens obtained at a single
endoscopy, while horizontally overlapped circles (no arrows) indicate
specimens obtained at temporally neighboring but separate endosco-
pies.
doi:10.1371/journal.pone.0001890.g006
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interval are as follows: two initial annual endoscopies, followed by a
3-year interval for BE cases without dysplasia, or less than 1 year for
BE with LGD until dysplasia is no longer found [21]. To simplify
calculations in the current study, we compared endoscopy savings
between a uniform 2-year follow-up protocol and our three-tiered
model. Using a simulation, we estimated that this 3-tiered risk
stratification strategy would save approximately 5,300 endoscopies
annually in the United States. If a 0.13% overall upper GI endoscopy
complication rate is assumed, this endoscopy savings would prevent
6.9 unnecessary complications annually in the United States [26].
These three risk tiers were defined using only progression status
at 2 years and 4 years after analyzed specimens were obtained.
Thus, theoretically, this stratification cannot guarantee differences
in progression-free survival more than 4 years after sampling.
However, Kaplan-Meier progression-free survival analysis
(Figure 5) demonstrated that our prediction model could
discriminate among the 3 risk groups well not only at 2 and
4 years post-sampling, but also over the entire follow-up period.
The Kaplan-Meier progression free survival curve showed that
some LR patients progressed soon after the fourth year following
their initial (index) BE EGD. However, the model recommends
follow-up endoscopy within 4 years after any LR EGD. For
example, patient #5i nFigure 6 had a LR specimen at 4.5 years
prior to progression. This case does not represent a flaw in the
model, since followup EGD was indeed performed as per the
model’s recommendation, and his risk level at 1.8 years before
progression was upgraded to HR.
In this study, there were 6 sets of multiple specimens from the
same timepoint in 5 patients (patients 4, 9, 15, 19, and 26; indicated
by arrows in Figure 6). The trained prediction model yielded
conflicting risk grade outputs in 3 specimen sets (patients 4, 15, and
26). One possible explanation for this observed discrepancy was
variation in biopsy sampling. Carcinogenic events, including
histologic [27], genomic [28], and epigenetic alterations [18], do
not occur uniformly throughout the BE epithelium. Therefore, as
with histologic assessment, this discrepancy could have been caused
by biopsy sampling variation. One potential solution to this issue is
to perform sampling from multiple anatomic loci, as in histological
assessment during current BE surveillance, and to apply the highest
risk assessment obtained from these multiple loci to scheduling of
the next BE surveilance endoscopy.
Our incremental analysis demonstrated that MI made a much
greater contribution to prediction accuracy than did the other
parameters. These findings are not surprising, since some
researchers have reported that MI or CpG Island Methylator
Phenotype (CIMP) status correlates with patient survival in
esophageal cancer [29] and other malignancies, such as colorectal
cancer [30] or neuroblastoma [31]. However, mechanism(s) by
which an ‘‘MI-high’’ epigenetic or methylator phenotype contrib-
utes to carcinogenesis remain(s) unclear. Possible explanations
include: 1) methylator phenotype-positive tumors tend to be
hypermethylated in promoter regions of other genes, including
tumor suppressor genes (such as APC, CDH1, TIMP3, and others)
[4]; 2) methylator phenotype-positive tumors tend to undergo
hMLH1 gene inactivation via promoter hypermethylation.
Although hMLH1 hypermethylation is relatively uncommon in
EAC compared to gastric, colorectal, or endometrial cancer [32],
hMLH1 hypermethylation in BE may cause microsatellite
instability in the coding regions of the tumor suppressor genes
[33]; 3) a methylator phenotype may be associated with chromatin
remodeling [34]; and 4) methylated cytosines are hotspots for
mutations, as with the p53 gene [35].
Histopathologic assessment of dysplasia in BE is currently the
most widely accepted parameter with which to predict BE
progression. However, histopathologic assessment is plagued by
inter-observer variation, which can lead to confusion during
clinical BE surveillance. One aim in this study was to develop
biomarkers that were more objective and quantifiable than
histopathologic assessment, such as epigenetic parameters (includ-
ing MI). However, MI data also risk being influenced by several
factors. One such factor is the dichotomization of normalized
methylation values (NMV) for each gene into positive vs. negative
classes. The significance and relevance to BE progression of
methylation of each gene may vary. For this reason, we did not use
uniform criteria to dichotomize NMV data, but rathere optimized
criteria for each gene based on ROC curve analysis. Another
factor potentially influencing MI data is endoscopic sampling bias.
Methylation status in BE occurs heterogeneously [32], as does
genomic clonality [28]. Therefore, multiple biopsies during each
endoscopic procedure are widely in BE surveillance.
In both the 2-year and 4-year prediction models, according to
incremental value analysis, pathological assessment was the
second-most influential parameter. The natural history of LGD
Table 3. Univariate analyses of incremental values.
sex SL pathology HPP1 p16 Runx3 MI
2-year prediction * * * *
minus 0.7546 0.7232 0.7178 0.7335 0.7211 0.7276 0.6932
plus 0.7402 0.7625 0.7720 0.7518 0.7644 0.7579 0.7908
increment 20.0144 0.0393 0.0542 0.0183 0.0433 0.0303 0.0977
p-value ,0.00001 0.00048 ,0.00001 0.13229 0.00058 0.01643 ,0.00001
4-year prediction * * *
minus 0.7057 0.6882 0.6879 0.6944 0.6919 0.6981 0.6652
plus 0.7192 0.7298 0.7341 0.7224 0.7254 0.7198 0.7509
increment 0.0135 0.0416 0.0462 0.0280 0.0335 0.0216 0.0857
p-value ,0.00001 0.00012 ,0.00001 0.01876 0.00576 0.02582 ,0.00001
SL: segment length; MI: methylation index; minus: median values of AUROCs in variable sets lacking indicated parameter; plus: median values of AUROCs in variable sets
containing indicated parameter; increment: differences of median values in minus and plus, which represents the impacts of individual parameters;
*: parameters
selected in the best parameter sets; p-value: p-values of paired t-tests.
doi:10.1371/journal.pone.0001890.t003
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ranging from 5-12.5% [36,37]. LGD also frequently regresses to
BE, at rates ranging as high as 60-75% [38,39]. In addition, the
histological diagnosis of dysplasia in BE [14,40], as well as in other
premalignant lesions (esophageal squamous epithelium [41],
stomach [42], ulcerative colitis [43], and others), is characterized
by high inter-observer variability. Therefore, the value of LGD as
a clinical cancer risk marker is controversial. However, some
studies have demonstrated that LGD is a risk factor for the
development of EAC in BE [13,39]. Our findings corroborated
this predictive value of LGD. In addition, our results emphasize
the power of combining pathological assessment with methylation
status to improve risk prediction accuracy.
In both the 2-year and 4-year models, segment length (SL) was
also one of the parameters in the most optimal parameter set.
Patients with long-segment ($3cm) BE are widely believed to
carry a greater risk of developing EAC than those with short-
segment BE [20]. However, other studies have demonstrated that
the risk of developing EAC in patients with short-segment BE is
not substantially lower than in patients with long-segment BE [44].
In the current study, SL was selected in the optimal parameter set
for both the 2-year and the 4-year models (Table 2). This finding
also suggests that SL is not strong as an independent clinical
marker; however, it does contribute significantly as a member of a
parameter set.
The NCI Early Detection Research Network (EDRN) defined
five phases of biomarker development in the early detection of
cancer [45]. Currently, flow cytometric (tetraploidy, aneuploidy)
[46] and loss of heterozygosity (LOH) at the p53 locus [47] have
advanced regarding biomarker validation in large-scale phase 4
studies as defined by EDRN classification. However, the AUROC
for prediction of BE progression (to EAC) based on flow cytometry
was 0.76 [46]. Thus, our multi-tiered prediction method based on
clinical and epigenetic parameters (AUROC=0.8387 and 0.7910
for the 2-year and 4-year models, respectively) exceeded published
AUROCs based on single flow cytometric analysis alone [46].
Moreover, assessment of aberrant methylation in BE can be
performed using formalin-fixed, paraffin-embedded specimens
[48]. Finally, matching normal tissue is not necessary for
methylation assays, in contrast to LOH. These advantageous
features of methylation-based biomarkers may make specimen
collection easier, thereby facilitating large-scale multi-institutional
prospective or retrospective studies.
The work described in this report is now the subject of an
EDRN Phase 3 validation study. In preparing to proceed to Phase
4 validation, we developed a prediction model to stratify BE
patients, validated our model, and estimated its potential clinical
impact (endoscopy savings) by applying a simulation. Because of
the rarity of BE progressor specimens, the number of progressor
patients and specimens was relatively small, despite collecting
them from two institutions. Further studies may be needed to
increase the number of BE progressor and non-progressor
specimens by collecting specimens from multiple additional
institutions prior to initiating a prospective Phase 4 study.
In conclusion, we developed a 3-tiered risk stratification strategy
for neoplastic progression prediction in BE patients, based on
epigenetic and clinical parameters. This strategy offers consider-
able promise to benefit the current BE surveillance health care
system.
Supporting Information
Figure S1 Simulation of endoscopy savings. Sample (P vs. NP)
proportions in this study are not identical to those in the clinical
setting. Thus, to estimate real sample proportions, we converted
Figure 4C, based on assumptions that the progression rate of BE in
4 years (=(P(0-2)+P(2-4))/(P(4-)+NP)) would be 1/25, and that the
proportion of HR, IR and LR in each sample group (P(0-2), P(2-4),
P(4-),NP) would be identical to proportions observed in Figure 4C.
In addition, total BE patient number was adjusted to the estimated
number (68,932) of currently diagnosed BE patients in the United
States. Numbers of endoscopies needed were calculated for a 2-
year uniform follow-up protocol and for our three-tiered
stratification approach.
Found at: doi:10.1371/journal.pone.0001890.s001 (0.74 MB TIF)
Figure S2 Permutation analysis. The arrow indicates the
AUROCs (0.8387 and 0.7910) of the original 2-year and 4-year
prediction models, respectively. Among 1000 AUROCs generated
by the permutation analysis, 3 and 4 AUROCs surpassed the
original AUROCs for 2- and 4-year model, respectively. This
permutation analysis indicated that AUROC in our original
prediction model were significantly better than AUROCs of the
null hypothesis, with a false discovery rate (FDR) of 0.003 and
0.004 for 2- and 4-year model, respectively.
Found at: doi:10.1371/journal.pone.0001890.s002 (0.92 MB TIF)
Text S1 1. Formula of Discriminant function 2. Estimation of
surveillance endoscopy savings 3. Incremental value analysis 4.
Permutation Analysis.
Found at: doi:10.1371/journal.pone.0001890.s003 (0.06 MB
DOC)
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